We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Molecular Templates Inc (MTEM) USD0.001

Sell:$0.94 Buy:$0.96 Change: $0.0583 (6.64%)
NASDAQ:2.09%
Market closed |  Prices as at close on 12 August 2022 | Switch to live prices |
Sell:$0.94
Buy:$0.96
Change: $0.0583 (6.64%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 12 August 2022 | Switch to live prices |
Sell:$0.94
Buy:$0.96
Change: $0.0583 (6.64%)
Market closed |  Prices as at close on 12 August 2022 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Molecular Templates, Inc. is a clinical stage biopharmaceutical company that is focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer and other serious diseases. The Company utilizes its biologic drug platform to design and generate engineered toxin bodies (ETBs). ETBs use a genetically engineered version of the Shiga-like Toxin A subunit (SLTA), a ribosome inactivating bacterial protein. The Company is developing ETBs for various targets, including CD20, CD38, HER2, and PD-L1. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of multiple myeloma. HER2 is clinically validated as a target for the treatment of solid tumors including breast and gastric cancer. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.

Contact details

Address:
9301 Amberglen Blvd Ste 100
AUSTIN
78729-1153
United States
Telephone:
+1 (512) 8961555
Website:
https://mtem.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MTEM
ISIN:
US6085501095
Market cap:
$47.89 million
Shares in issue:
56.34 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Jason Kim
    President, Chief Operating Officer
  • Eric Poma
    Chief Executive Officer, Chief Scientific Officer, Director
  • Sean McLennan
    Interim Chief Financial Officer, Senior Vice President - Finance, Principal Accounting Officer, Corporate Controller, Treasurer
  • Megan Filoon
    General Counsel
  • Roger Waltzman
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.